Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter?

Chang K. C., Leung C. C., Yew W. W., Tam C. M.

Source: Eur Respir J 2007; 29: 347-351
Journal Issue: February
Disease area: Respiratory infections

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Chang K. C., Leung C. C., Yew W. W., Tam C. M.. Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter?. Eur Respir J 2007; 29: 347-351

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Early dosing schedules of pyrazinamide-containing anti-TB treatment have no significant impact on drug-induced hepatitis
Source: ISSN=ISSN 1810-6838, ISBN=, page=69
Year: 2007

New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon?
Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem
Year: 2005

Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis
Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics
Year: 2016


Prevalence of inappropriate tuberculosis treatment regimens: a systematic review
Source: Eur Respir J 2012; 39: 1012-1020
Year: 2012



The side-effects of TB therapy: myth and reality
Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties
Year: 2005


Evaluation of drug induced liver injury due to anti tuberculous drugs in directly observed daily therapy
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016


Patient choice promotes adherence in preventive treatment for latent tuberculosis
Source: Eur Respir J 2007; 30: 728-735
Year: 2007



Efficacy and safety of modified anti-tubercular treatment(ATT) regimens in treatment of tuberculosis(TB) in patients with underlying chronic liver disease(CLD)
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016



Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment
Source: Annual Congress 2007 - Clinical tuberculosis
Year: 2007


Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions?
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016


Incidence and timing of hepatotoxicity due to anti-tuberculous treatment
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011

Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016


Antituberculosis drug-induced hepatotoxicity: influence on the management and outcome of active tuberculosis (TB)
Source: Annual Congress 2007 - Epidemiology of tuberculosis II
Year: 2007


Side effects of tuberculosis treatment with fixed-dose combinations
Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics
Year: 2016


Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs
Source: Eur Respir J, 55 (3) 1902048; 10.1183/13993003.02048-2019
Year: 2020



Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is the benefit?
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011


The effectiveness of pulmonary TB treatment in patients with organic liver diseases, depending on the way of administration of anti-TB drugs
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016


Opportunities of application of short regimens for MDR-TBat the expense of using intravenous administration of anti-TB drugs during intensive phase
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016


Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013


Anti-tuberculosis drug concentrations and treatment outcomes in patients with both tuberculosis and HIV infection
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Year: 2013